Kestra Private Wealth Services LLC Sells 9,161 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Kestra Private Wealth Services LLC reduced its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 49.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 9,314 shares of the biopharmaceutical company's stock after selling 9,161 shares during the period. Kestra Private Wealth Services LLC's holdings in Halozyme Therapeutics were worth $445,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of HALO. Congress Asset Management Co. raised its holdings in Halozyme Therapeutics by 446.5% during the 3rd quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company's stock worth $139,298,000 after buying an additional 1,988,238 shares during the period. Janney Montgomery Scott LLC raised its holdings in shares of Halozyme Therapeutics by 698.8% in the fourth quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company's stock valued at $13,756,000 after purchasing an additional 251,711 shares during the last quarter. Boston Trust Walden Corp raised its holdings in shares of Halozyme Therapeutics by 54.0% in the third quarter. Boston Trust Walden Corp now owns 682,616 shares of the biopharmaceutical company's stock valued at $39,073,000 after purchasing an additional 239,321 shares during the last quarter. South Street Advisors LLC acquired a new stake in shares of Halozyme Therapeutics in the third quarter valued at approximately $9,812,000. Finally, Hantz Financial Services Inc. acquired a new stake in shares of Halozyme Therapeutics in the third quarter valued at approximately $9,260,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. HC Wainwright lifted their price objective on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the company a "buy" rating in a report on Wednesday. JMP Securities lifted their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a "market outperform" rating in a report on Friday, November 1st. Wells Fargo & Company lowered their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Finally, Piper Sandler boosted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a report on Friday, January 10th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $61.11.

Insiders Place Their Bets

In other news, Director Jeffrey William Henderson sold 5,000 shares of the business's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the sale, the director now owns 38,611 shares of the company's stock, valued at approximately $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 2.40% of the company's stock.

Halozyme Therapeutics Stock Performance

HALO stock traded down $0.13 during midday trading on Wednesday, reaching $57.77. 2,236,459 shares of the company were exchanged, compared to its average volume of 1,306,418. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The business has a 50-day moving average price of $53.07 and a two-hundred day moving average price of $54.56. Halozyme Therapeutics, Inc. has a one year low of $35.50 and a one year high of $65.53. The firm has a market capitalization of $7.35 billion, a price-to-earnings ratio of 19.13, a price-to-earnings-growth ratio of 0.44 and a beta of 1.25.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 41.43% and a return on equity of 179.82%. The firm had revenue of $298.01 million during the quarter, compared to analysts' expectations of $285.74 million. Equities research analysts forecast that Halozyme Therapeutics, Inc. will post 3.87 EPS for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.